Financings
• Agennix AG obtained a $19.3 million loan from one of its shareholders.
• Cerenis Therapeutics SA raised $51.9 million in a Series C financing.
• Immune Design Corp. raised $32 million in Series B funding.
• XOMA Ltd. secured a $30 million committed equity financing facility.
Deals
• NovImmune SA licensed a preclinical anti-IL17 antibody program to Genentech Inc./Roche AG (no terms).
• Regeneron Pharmaceuticals Inc. expanded its non-exclusive VelocImmune mouse antibody deal with Astellas Pharma Inc. for $165 million up front.
. . . And More
• Genzyme Corp.'s stock got a bump on rumors of takeover interest from Sanofi-Aventis SA.
• Momenta Pharmaceuticals Inc. got FDA approval of its generic Lovenox (enoxaparin, Sanofi-Aventis SA).
• Onyx Pharmaceuticals Inc.'s carfilzomib generated good Phase IIb data for multiple myeloma.
• Allos Therapeutics Inc.'s shares dipped on word of second-quarter earnings and lower-than-expected Folotyn sales.
• Genzyme Corp.'s shares rose more on continued speculation of a buyout by Sanofi-Aventis SA.